The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer

被引:16
作者
Deng, XH [1 ]
Hogdall, EVS
Hogdall, CK
Norgaard-Pedersen, B
Jorgensen, M
Nielsen, H
Engelholm, SAA
机构
[1] Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China
[2] Danish Canc Soc, Div Canc Epidemiol, DK-2100 Copenhagen, Denmark
[3] Rigshosp, Juliane Marie Ctr, Gynecol Clin, DK-2100 Copenhagen, Denmark
[4] Rigshosp, Statens Serum Inst, Dept Clin Biochem, DK-2100 Copenhagen, Denmark
[5] Rigshosp, Dept Oncol, Finsen Ctr, DK-2100 Copenhagen, Denmark
关键词
tetranectin; CA-125; ovarian cancer; prognostic factor; neoplasm recurrence;
D O I
10.1006/gyno.2000.5996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of the study was to examine the prognostic values of, respectively, tetranectin (TN) and CA-125 measured in serum from patients presenting with relapse of ovarian cancer (OC). Methods. TN and CA-125 were measured in serum samples from 75 patients with relapse of OC before the start of second-line chemotherapy. The endpoint used was death of OC. The variables were analyzed by univariate life table analysis and multivariate Cox analysis. Results. A significantly shortened survival was found for patients with low serum TN values compared to patients with serum TN levels above one of the cutoff levels. The survivals are illustrated by life tables. No prognostic function was found for CA-125, TN and relapse less than or equal to 12 months after primary treatment were the only significant independent prognostic variables among the following variables tested in the Cox analyses: primary and second-line treatment, CA-125, age, histology, performance score, tumor localization, and size. Conclusion. Serum TN determination may be valuable in the selection of patients with relapse of OC for new treatment strategies in future studies. (C) 2000 academic Press.
引用
收藏
页码:416 / 419
页数:4
相关论文
共 22 条
[1]   FIBRIN DEGRADATION PRODUCTS AND OVARIAN TUMOURS [J].
ASTEDT, B ;
SVANBERG, L ;
NILSSON, IM .
BRITISH MEDICAL JOURNAL, 1971, 4 (5785) :458-&
[2]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[3]   TUMOR REDUCTION SURGERY AND LONG-TERM SURVIVAL IN ADVANCED OVARIAN-CANCER - A DACOVA STUDY [J].
BERTELSEN, K .
GYNECOLOGIC ONCOLOGY, 1990, 38 (02) :203-209
[4]   Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital [J].
Bjorge, T ;
Engeland, A ;
Sundfor, K ;
Trope, CG .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (07) :777-781
[6]   PURIFICATION AND CHARACTERIZATION OF A NOVEL, OLIGOMERIC, PLASMINOGEN KRINGLE 4 BINDING-PROTEIN FROM HUMAN PLASMA-TETRANECTIN [J].
CLEMMENSEN, I ;
PETERSEN, LC ;
KLUFT, C .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 156 (02) :327-333
[7]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[8]  
deVries TJ, 1996, J PATHOL, V179, P260, DOI 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO
[9]  
2-T
[10]  
HOGDALL CK, 1993, CANCER, V72, P2415